ZCM
NKTR icon

Zebra Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Zebra Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-483
Closed -$258K – 371
2019
Q2 		$258K Buy
+483
New +$242K 0.13% 353

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Zebra Capital Management's NKTR Position: Q3 2019 in Review

Zebra Capital Management sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 483 shares — an estimated $258K sold.

Zebra Capital Management first reported a position in NKTR in Q2 2019 and held it in 1 quarter. The position peaked at $258K in Q2 2019. 288 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • Zebra Capital Management reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Zebra Capital Management sold 483 Nektar Therapeutics shares in Q3 2019, an estimated $258K.
  • Zebra Capital Management first reported a position in Nektar Therapeutics in Q2 2019 and held it in 1 quarter.
  • Zebra Capital Management's Nektar Therapeutics position peaked at $258K in Q2 2019.
  • 288 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on Zebra Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.